Pelthos Therapeutics (PTHS) – Research Analysts’ Recent Ratings Changes

A number of firms have modified their ratings and price targets on shares of Pelthos Therapeutics (NYSEAMERICAN: PTHS) recently:

• 4/1/2026 – Pelthos Therapeutics is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $50.00 price target on the stock.
• 3/24/2026 – Pelthos Therapeutics was upgraded by Zacks Research from “strong sell” to “hold”.
• 3/20/2026 – Pelthos Therapeutics had its price target raised by Oppenheimer Holdings, Inc. from $60.00 to $62.00. They now have an “outperform” rating on the stock.
• 3/19/2026 – Pelthos Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $60.00 price target on the stock.
• 2/27/2026 – Pelthos Therapeutics is now covered by Piper Sandler. They set an “overweight” rating and a $48.00 price target on the stock.
• 2/26/2026 – Pelthos Therapeutics had its price target lowered by Roth Mkm from $57.00 to $55.00. They now have a “buy” rating on the stock.

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).